What is Palvella's gross profit margin?

What were the key takeaways from Palvella's earnings call?

Did Palvella beat or miss consensus estimates last quarter?

What were the key takeaways from Palvella’s earnings call?

What guidance did Palvella's management provide for the next earnings period?

What does Palvella do and what are its main business segments?

What factors drove the changes in Palvella's revenue and profit?

What is Palvella's latest dividend and current dividend yield?

- **FDA Milestones Achieved**: Rolling review and first module submission for QTORIN rapamycin NDA; on track for H1 2027 approval.
- **Pipeline Expansion**: Four rare disease indications with >300,000 U.S. patients targeted; Fast Track Designations for two programs.
- **Commercial Strength**: $250M cash, 40 sales reps, and internal patient services team for rapid launch.
- ** Physician Demand**: >80% of surveyed doctors willing to prescribe QTORIN as first-line therapy for four rare diseases.
- **Financial Flexibility**: $230M capital raise supports aggressive commercial and pipeline execution.

**【CEO Summary Section】**
- Achieved three key milestones: compelling phase III SELVA study results, FDA rolling review, and NDA module submission. On track for full NDA submission in H2 2026 and potential FDA approval in H1 2027.
- Expanded QTORIN rapamycin pipeline with Fast Track Designations for cutaneous venous malformations and clinically significant angiokeratomas, targeting >300,000 U.S. patients across four indications.
- Commercial readiness includes 40 sales reps, medical science liaisons, and patient services team; $250M cash balance supports launch.
- Physician survey shows >80% interest in QTORIN as first-line therapy for four rare diseases.

**【CFO Financial Commentary】**
- $251M cash balance as of Q2 2026, supported by $230M capital raise in Q1 2026.
- 2026 cash spend expected at $85M-$95M, driven by commercial and medical affairs investments (e.g., expanded sales force, disease awareness campaigns).
- Financial flexibility to advance pipeline and support standalone launch of QTORIN rapamycin.

**【Q&A Highlights】**
- **Patient Identification**: Confirmed >30,000 diagnosed microcystic LM patients in U.S.; 400 high-volume vascular anomaly centers identified for targeted engagement.
- **Pipeline Cadence**: Phase III cutaneous venous malformations study to begin Q4 2026; DSAP phase II initiation in Q4 2026; angiokeratoma phase II data expected H2 2027.
- **Reimbursement Strategy**: Payer research supports orphan pricing ($100K-$200K/year); no prior authorization for unapproved therapies expected.
- **Breakthrough Therapy Designation**: Resubmission planned post-Phase III data; FDA collaboration on phase III study design for CVM.
- **Platform Designation**: Potential future benefit for QTORIN pitavastatin and third product candidate post-approval.


PVLA

PVLA

Palvella (PVLA) Financials Overview

PVLA Q2 2026 Earnings

Earnings

EPS

Revenue

Revenue & Expenses

Key Indicators

Income Statement

Trend

Breakdown

Balance Sheet

Trend

Breakdown

Cash Flow

Trend

Breakdown

Revenue Breakdown

By Business

By Region

Dividend

Payout Ratio

Dividend Yield

You can ask Aime